<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00294788</url>
  </required_header>
  <id_info>
    <org_study_id>ProFlu2006</org_study_id>
    <secondary_id>H05/123</secondary_id>
    <nct_id>NCT00294788</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Effectiveness of a Probiotic Bacterium to Boost the Immune Response to Influenza Vaccines</brief_title>
  <official_title>Phase I/II Placebo-Controlled Study of Consumption of a Probiotic on HAI Titre Following Influenza Vaccination of Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Probiomics Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Probiomics Ltd</source>
  <brief_summary>
    <textblock>
      This project aims to test the hypothesis that oral consumption of a specific strain of the
      probiotic bacterium Lactobacillus fermentum (trademarked PCC速) is able to significantly
      enhance the immune response to a vaccine for influenza.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2006</start_date>
  <completion_date>January 2007</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage enhancement of the immune response to Fluvax vaccine by PCC速 compared to placebo as measured by hemagglutination inhibition (HAI) titre in the serum of subjects 4 weeks after vaccination</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase in T cell cytokine expression; Decrease in incidence of respiratory tract illness, an improvement in general intestinal health, and a reduction in the severity of adverse side effects of the injection</measure>
  </secondary_outcome>
  <enrollment>300</enrollment>
  <condition>Influenza</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluvax</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PCC速 (Lactobacillus fermentum VRI 003)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persons must be adult men and women aged 18-49 years (have not reached 50th birthday).

          -  Persons must be able and willing to provide informed consent.

          -  Persons must be willing to receive the influenza vaccine (Fluvax速) given as an
             intramuscular injection.

          -  Persons must be willing to consume one gelatin capsule per day containing either
             probiotic bacteria or placebo (inactive substance) for the duration (42 days) of the
             study.

          -  Persons must be willing to provide blood specimens, each of 10 ml, collected by
             venepuncture.

          -  Persons must be willing to notify study personnel of a range of health effects by
             questionnaire.

        Exclusion Criteria:

          -  Any health condition for which the influenza vaccine is not recommended including:
             chronic diseases of the pulmonary or cardiovascular systems (including asthma);
             chronic metabolic diseases (including diabetes); renal dysfunction;
             hemoglobinopathies; immune deficiency diseases (including HIV infection) or on-going
             immunosuppressive therapy.

          -  Currently pregnant; nursing mothers; or planning a pregnancy within one month of
             vaccination.

          -  Allergy to latex, egg, or egg protein, or the antibiotics neomycin or polymyxin.

          -  A prior serious reaction to a vaccine, or have had Guillain-Barre syndrome.

          -  Received an influenza vaccine in the past.

          -  Received any other vaccine within one month prior to enrolment

          -  Are participating in another research study involving any study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Penny, DSc, MD, FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Good Health Solutions</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Good Health Solutions</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <reference>
    <citation>Mohamadzadeh M, Olson S, Kalina WV, Ruthel G, Demmin GL, Warfield KL, Bavari S, Klaenhammer TR. Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2880-5. Epub 2005 Feb 14.</citation>
    <PMID>15710900</PMID>
  </reference>
  <reference>
    <citation>Prescott SL, Dunstan JA, Hale J, Breckler L, Lehmann H, Weston S, Richmond P. Clinical effects of probiotics are associated with increased interferon-gamma responses in very young children with atopic dermatitis. Clin Exp Allergy. 2005 Dec;35(12):1557-64.</citation>
    <PMID>16393321</PMID>
  </reference>
  <reference>
    <citation>Weston S, Halbert A, Richmond P, Prescott SL. Effects of probiotics on atopic dermatitis: a randomised controlled trial. Arch Dis Child. 2005 Sep;90(9):892-7. Epub 2005 Apr 29.</citation>
    <PMID>15863468</PMID>
  </reference>
  <reference>
    <citation>Qi H, Denning TL, Soong L. Differential induction of interleukin-10 and interleukin-12 in dendritic cells by microbial toll-like receptor activators and skewing of T-cell cytokine profiles. Infect Immun. 2003 Jun;71(6):3337-42.</citation>
    <PMID>12761116</PMID>
  </reference>
  <verification_date>January 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2006</study_first_submitted>
  <study_first_submitted_qc>February 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2006</study_first_posted>
  <last_update_submitted>January 8, 2007</last_update_submitted>
  <last_update_submitted_qc>January 8, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2007</last_update_posted>
  <keyword>Influenza</keyword>
  <keyword>bioadjuvant</keyword>
  <keyword>probiotic</keyword>
  <keyword>HAI</keyword>
  <keyword>immunity</keyword>
  <keyword>vaccine</keyword>
  <keyword>Immune response to influenza vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

